StemCell Therapy

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Quarter Results/Quarterly / Interim StatementB.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN is pleased with its results for the first nine months of the 2019/20 financial year

31.08.2020 / 08:30 The issuer is solely responsible for the content of this announcement.

BRAIN is pleased with its results for the first nine months of the 2019/20 financial year

Zwingenberg, Germany31 August 2020

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG, ISIN DE0005203947 / WKN 520394) today published its results for the first nine months of the 2019/20 financial year. Accordingly, the BRAIN Group reports revenues of ? 29.6 million compared to ? 27.9 million in the same period of the previous year. Taking into account the deconsolidation of Monteil Cosmetics GmbH, this corresponds to organic growth of 12.2%.

Third quarter revenues increased by 8.4% to ? 9.6 million from ? 8.9 million in the same period last year. This growth was purely organic, achieved in both the BioScience and BioIndustrial segments.

"Particularly considering the general economic situation, we have achieved very good growth," says Manfred Bender, CFO of BRAIN AG. "The fact that this growth is more pronounced in our research-driven segment is again due to the higher business volume with existing customers as well as new contracts for tailormade solutions projects."

Development by segments

The BioScience segment generated revenues of ? 10.5 million in the reporting period, up 37.5% from the prior-year period. Adjusted EBITDA improved from ? -4.4 million to ? -3.1 million.

Revenues of the BioIndustrial segment, which is related to product sales, decreased by 5.9% from ? 20.3 million to ? 19.1 million in the reporting period. Organically, revenues here increased by ? 0.4 million or 2.1% from ? 18.7 million to ? 19.1 million. The adjusted EBITDA of the segment developed positively and increased by 9.2% from ? 2.3 million to ? 2.6 million. This corresponds to an adjusted EBITDA margin of 13.3% compared to 11.5% in the previous year.

The reasons for the weaker revenue growth in the product business are, in addition to the start of new production facilities in Cardiff (UK) and Bttelborn, the globally reduced demand for bioethanol and alcoholic beverages due to the Corona pandemic. The BRAIN subsidiary WeissBioTech supplies, among others, powerful enzymes to bioethanol producers and the wine industry.

Despite the ongoing Corona virus pandemic and the associated economic uncertainty, BRAIN AG is still confident to make further progress in the projected direction, albeit possibly at a slightly slower pace.

Key financials (first nine months of fiscal year 2019/20)

More detailed information on the financial results are available at http://www.brain-biotech.com/investors/financial-publications as part of the quarterly statement for the period ended 30 June 2020.

Financial Calendar:

http://www.brain-biotech.com/investors/financial-calendar

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by means of "Nature's Toolbox" are successfully applied in the chemicals, cosmetics and food industries.

BRAIN's business model is based on two pillars. The BioScience segment mainly comprises research and development business with industrial partners ("Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products.

B.R.A.I.N.Biotechnology ResearchAnd Information Network AGDarmstdter Str. 34-3664673 ZwingenbergGermanywww.brain-biotech.com

Contact Investor RelationsMichael SchneidersPhone: +49-6251-9331-86Email: mis@brain-biotech.com

Contact MediaDr. Stephanie KonlePhone: +49-(0)-6251-9331-70Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)

31.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Continue reading here:
BRAIN Biotechnology Research And Information Network AG: BRAIN is pleased with its results for the first nine months of the 2019/20 financial year -...

The 39 rating InvestorsObserver gives to Menlo Therapeutics Inc (MNLO) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 29 percent of stocks in the Biotechnology industry, MNLOs 39 overall rating means the stock scores better than 39 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 39 would rank higher than 39 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Menlo Therapeutics Inc (MNLO) stock has risen 4.73% while the S&P 500 is lower by -0.03% as of 3:12 PM on Monday, Aug 31. MNLO is up $0.07 from the previous closing price of $1.48 on volume of 1,790,999 shares. Over the past year the S&P 500 has gained 20.67% while MNLO is lower by -67.98%. MNLO lost -$3.75 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Menlo Therapeutics Inc click here.

Read more from the original source:
Is Menlo Therapeutics Inc (MNLO) a Winner in the Biotechnology Industry? - InvestorsObserver

Iovance Biotherapeutics Inc (IOVA) is near the middle in its industry group according to InvestorsObserver. IOVA gets an overall rating of 51. That means it scores higher than 51 percent of stocks. Iovance Biotherapeutics Inc gets a 53 rank in the Biotechnology industry. Biotechnology is number 23 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Iovance Biotherapeutics Inc (IOVA) stock is higher by 4.39% while the S&P 500 has fallen -0.08% as of 11:20 AM on Monday, Aug 31. IOVA has risen $1.39 from the previous closing price of $31.68 on volume of 584,032 shares. Over the past year the S&P 500 is up 20.60% while IOVA has risen 63.15%. IOVA lost -$1.93 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Iovance Biotherapeutics Inc click here.

More:
Is Iovance Biotherapeutics Inc (IOVA) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 63 rating InvestorsObserver gives to Heat Biologics Inc (HTBX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, HTBXs 63 overall rating means the stock scores better than 63 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Heat Biologics Inc (HTBX) stock is trading at $1.26 as of 9:52 AM on Monday, Aug 31, a decline of -$0.08, or -5.97% from the previous closing price of $1.34. The stock has traded between $1.25 and $1.36 so far today. Volume today is below average. So far 1,467,087 shares have traded compared to average volume of 35,406,604 shares.

To see InvestorsObserver's Sentiment Score for Heat Biologics Inc click here.

Read the original here:
Is Heat Biologics Inc (HTBX) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

TheGlobal Agricultural Biotechnology Market To Gain Massive Profits During Projected TimespanA fundamental outline of theAgricultural Biotechnology Marketniche is presented by the Agricultural Biotechnology Market report that entails definitions, classifications, applications together with industry chain framework. TheAgricultural Biotechnology Marketreport provides a far-reaching evaluation of necessary market dynamics and the latest trends. It also highlights the regional market, the prominent market players, as well as several market segments [Product, Applications, End-Users, and Major Regions], and sub-segments with a wide-ranging consideration of numerous divisions with their applications.

Request Free Sample Report of Agricultural Biotechnology Market Report @https://www.zionmarketresearch.com/sample/agricultural-biotechnology-market

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

Some of the Major Market Players Are:

Monsanto, Vilmorin, Bayer CropScience, Syngenta, Certis, DuPont Pioneer Hi-Bred, Evogene, KWS SAAT, Dow AgroSciences

Further, the report acknowledges that in these growing and promptly enhancing market circumstances, the most recent advertising and marketing details are very important to determine the performance in the forecast period and make essential choices for profitability and growth of the Agricultural Biotechnology Market. In addition, the report encompasses an array of factors that impact the growth of the Agricultural Biotechnology Market in the forecast period. Further, this specific analysis also determines the impact on the individual segments of the market.

Furthermore, the study assessed major market elements, covering the cost, capacity utilization rate, growth rate, capacity, production, gross, usage, revenue, export, supply, price, market share, gross margin, import, and demand. In addition, the study offers a thorough segmentation of the global Agricultural Biotechnology Market on the basis of geography [ Latin America, North America, Asia Pacific, Middle & East Africa, and Europe] , technology, end-users, applications, and region.

Download Free PDF Report Brochure@https://www.zionmarketresearch.com/requestbrochure/agricultural-biotechnology-market

The Agricultural Biotechnology Market report is a collection of pragmatic information, quantitative and qualitative estimation by industry experts, the contribution from industry connoisseurs and industry accomplices across the value chain. Furthermore, the report also provides the qualitative results of diverse market factors on its geographies and segments.

The Agricultural Biotechnology Market report is an appropriate compilation of all necessary data for the residential, industrial. & commercials buyers, manufacturers, governments, and other stakeholders to implement their market-centric tactics in line with the projected as well as the prevailing trends in the Agricultural Biotechnology Market. Apart from this, the report also provides insightful particulars of the existing policies, laws, together with guidelines.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/agricultural-biotechnology-market

Promising Regions & Countries Mentioned In The Agricultural Biotechnology Market Report:

Chapters Covered in Research Report are :

Chapter 1,2 :The goal of global Agricultural Biotechnology Market covering the market introduction, product image, market summary and development scope.

Chapter 3, 4 :Global Market Competitions by Manufacturers, Sales Volume and Market Profit.

Chapter 5,6,7:Global Supply (Production), Consumption, Export, Import by Regions like United States, Asia-Pacific, China, India, Japan. Conducts the region-wise study of the market based on the sales ratio in each region, and market share from 2015 to 2024

Chapter 8,9,10:Global Market Analysis by Application, Cost Analysis, Marketing Strategy Analysis, Distributors/Traders

Chapter 11,12 :Market information and study conclusions, appendix and data sources.

The market report also identifies further useful and usable information about the industry mainly includes Agricultural Biotechnology Market development trend analysis, investment return and feasibility analysis. Further, SWOT analysis is deployed in the report to analyze the key global market players growth in the Agricultural Biotechnology Market industry

Purposes Behind Buying Agricultural Biotechnology Market Report:-

Key questions answered in this comprehensive study Global Agricultural Biotechnology Market Size, Status and Forecast 2026

Request the coronavirus impact analysis across industries and market

Request impact analysis on this markethttps://www.zionmarketresearch.com/custom/8?covid19=true

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

View original post here:
Global Agricultural Biotechnology Market To Gain Massive Profits During Projected Timespan - Galus Australis

BEDFORD, N.H., Aug. 27, 2020 /PRNewswire/ --LSNE Contract Manufacturing, a leading contract development and manufacturing organization, is pleased to announce that the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved the manufacturing of clinical stage biotechnology based therapeutic products at its aseptic fill finish facility in Len, Spain. This important approval builds upon LSNE's well-established capabilities in providing aseptic fill finish of biologic products for clients at its US facilities. These products include monoclonal antibodies, fusion proteins, replacement enzymes, plasmids, capsids, and oligonucleotides.

"The authorization of biologic manufacturing for clinical drug product in both vial and pre-filled syringe (PFS) presentations is a vital step to our maturation of drug product manufacturing at our facility in Spain. This will provide the global market with more access to LSNE facilities for the manufacture of these high-value biologics, including monoclonal antibodies and other recombinant proteins," said Shawn Cain, LSNE's Chief Operating Officer.

Jaime Del Campo, Site Head at LSNE-Len said, "We are thrilled with this most recent milestone and our ongoing partnership with AEMPS. This is another big step forward supported by our industry leading quality and operations teams. We anticipate this authorization will have an immediate impact in our ability to support our client's varied clinical programs and ensures long-term benefits to their future commercial supply."

About LSNE

LSNE is a privately held company with six GMP facilities four located in New Hampshire, one in Wisconsin and one located in Len, Spain. LSNE has been providing contract lyophilization services to the pharmaceutical, biotechnology, and medical device industries since 1997, specializing in a wide range of services including process cycle development, fill-finish and lyophilization (for vials, pre-filled syringes and dropper bottles for ophthalmics), and analytical testing. Through the thoughtful integration of six processing facilities, qualified staffing, and extensive manufacturing history, LSNE is strategically positioned to provide products and services for clinical through commercial supply for pharmaceuticals and medical devices to a global market.

Media Contact

Jeff ClementVice President of Business Development(603) 668-5763info@lyophilization.comwww.lyophilization.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/lsne-leon-receives-approval-from-aemps-to-manufacture-biotechnology-based-therapeutic-products-301119798.html

SOURCE LSNE Contract Manufacturing

Link:
LSNE-Len Receives Approval From AEMPS To Manufacture Biotechnology Based Therapeutic Products - BioSpace

Albendazole Veterinary Drug Market Los Angeles, United State,, The global Albendazole Veterinary Drug market is expected to surge at a steady CAGR in the coming years, states the latest QY Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Albendazole Veterinary Drug market. Analysts have used Porters five forces analysis and SWOT analysis to explain the various elements of the market in absolute detail. Furthermore, it also studies the socio-economic factors, political changes, and environmental norms that are likely to affect the global Albendazole Veterinary Drug market.

The research report is committed to giving its readers an unbiased point of view of the global Albendazole Veterinary Drug market. Thus, along with statistics, it includes opinions and recommendation of market experts. This allows the readers to acquire a holistic view of the global market and the segments therein. The research report includes the study of the market segments on the basis of type, application, and region. This helps in identifying segment-specific drivers, restraints, threats, and opportunities.

Get PDF template of this report: https://www.qyresearch.com/sample-form/form/1702061/covid-19-impact-on-global-albendazole-veterinary-drug-market

The following Companies as the Key Players in the Global Albendazole Veterinary Drug Market Research Report:

, GSK, Sequent Scientific, Zoetis, AdvaCare Pharma, Guangdong Tianbao Biological Pharmaceutical Co., Ltd., Hanzhonghe Times Biotechnology Co., Ltd., Yahui Medicine, Beijing Shengmu Biotechnology Co., Ltd., Hebei Huabang Biological Technology Co., Ltd., Dongguan Meidehao Animal Pharmaceutical Co., Ltd., Sichuan Jinfeng Technology, Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd., Anhui Shenhui Agricultural Technology Co., Ltd., Foshan Zhengdian Biotechnology Co., Ltd., Shanghai Shenya, Tianjin Bijia Pharmaceutical Co., Ltd., Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province, Shimu Group, CSTP, Sneha Medicare Albendazole Veterinary Drug

Albendazole Veterinary Drug Market Product Type Segments

, Capsule Product, Table Product Albendazole Veterinary Drug

Albendazole Veterinary Drug Market Application Segments?<

Swine, Cattle, Others

Regions Covered in the Global Albendazole Veterinary Drug Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The scope of the Report:

The research report on the global Albendazole Veterinary Drug market is a comprehensive publication that aims to identify the financial outlook of the market. For the same reason, it offers a detailed understanding of the competitive landscape. It studies some of the leading players, their management styles, their research and development statuses, and their expansion strategies.The report also includes product portfolios and the list of products in the pipeline. It includes a thorough explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Enquire for customization in Report @https://www.qyresearch.com/customize-request/form/1702061/covid-19-impact-on-global-albendazole-veterinary-drug-market

Strategic Points Covered in TOC:

1 Study Coverage 1.1 Albendazole Veterinary Drug Product Introduction 1.2 Market Segments 1.3 Key Albendazole Veterinary Drug Manufacturers Covered: Ranking by Revenue 1.4 Market by Type1.4.1 Global Albendazole Veterinary Drug Market Size Growth Rate by Type1.4.2 Capsule Product1.4.3 Table Product 1.5 Market by Application1.5.1 Global Albendazole Veterinary Drug Market Size Growth Rate by Application1.5.2 Swine1.5.3 Cattle1.5.4 Others 1.6 Coronavirus Disease 2019 (Covid-19): Albendazole Veterinary Drug Industry Impact1.6.1 How the Covid-19 is Affecting the Albendazole Veterinary Drug Industry

1.6.1.1 Albendazole Veterinary Drug Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Albendazole Veterinary Drug Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Albendazole Veterinary Drug Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary 2.1 Global Albendazole Veterinary Drug Market Size Estimates and Forecasts2.1.1 Global Albendazole Veterinary Drug Revenue 2015-20262.1.2 Global Albendazole Veterinary Drug Sales 2015-2026 2.2 Albendazole Veterinary Drug Market Size by Region: 2020 Versus 20262.2.1 Global Albendazole Veterinary Drug Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Albendazole Veterinary Drug Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Albendazole Veterinary Drug Competitor Landscape by Players 3.1 Albendazole Veterinary Drug Sales by Manufacturers3.1.1 Albendazole Veterinary Drug Sales by Manufacturers (2015-2020)3.1.2 Albendazole Veterinary Drug Sales Market Share by Manufacturers (2015-2020) 3.2 Albendazole Veterinary Drug Revenue by Manufacturers3.2.1 Albendazole Veterinary Drug Revenue by Manufacturers (2015-2020)3.2.2 Albendazole Veterinary Drug Revenue Share by Manufacturers (2015-2020)3.2.3 Global Albendazole Veterinary Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Albendazole Veterinary Drug Revenue in 20193.2.5 Global Albendazole Veterinary Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Albendazole Veterinary Drug Price by Manufacturers 3.4 Albendazole Veterinary Drug Manufacturing Base Distribution, Product Types3.4.1 Albendazole Veterinary Drug Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Albendazole Veterinary Drug Product Type3.4.3 Date of International Manufacturers Enter into Albendazole Veterinary Drug Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Albendazole Veterinary Drug Market Size by Type (2015-2020)4.1.1 Global Albendazole Veterinary Drug Sales by Type (2015-2020)4.1.2 Global Albendazole Veterinary Drug Revenue by Type (2015-2020)4.1.3 Albendazole Veterinary Drug Average Selling Price (ASP) by Type (2015-2026) 4.2 Global Albendazole Veterinary Drug Market Size Forecast by Type (2021-2026)4.2.1 Global Albendazole Veterinary Drug Sales Forecast by Type (2021-2026)4.2.2 Global Albendazole Veterinary Drug Revenue Forecast by Type (2021-2026)4.2.3 Albendazole Veterinary Drug Average Selling Price (ASP) Forecast by Type (2021-2026) 4.3 Global Albendazole Veterinary Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026) 5.1 Global Albendazole Veterinary Drug Market Size by Application (2015-2020)5.1.1 Global Albendazole Veterinary Drug Sales by Application (2015-2020)5.1.2 Global Albendazole Veterinary Drug Revenue by Application (2015-2020)5.1.3 Albendazole Veterinary Drug Price by Application (2015-2020) 5.2 Albendazole Veterinary Drug Market Size Forecast by Application (2021-2026)5.2.1 Global Albendazole Veterinary Drug Sales Forecast by Application (2021-2026)5.2.2 Global Albendazole Veterinary Drug Revenue Forecast by Application (2021-2026)5.2.3 Global Albendazole Veterinary Drug Price Forecast by Application (2021-2026) 6 North America 6.1 North America Albendazole Veterinary Drug by Country6.1.1 North America Albendazole Veterinary Drug Sales by Country6.1.2 North America Albendazole Veterinary Drug Revenue by Country6.1.3 U.S.6.1.4 Canada 6.2 North America Albendazole Veterinary Drug Market Facts & Figures by Type 6.3 North America Albendazole Veterinary Drug Market Facts & Figures by Application 7 Europe 7.1 Europe Albendazole Veterinary Drug by Country7.1.1 Europe Albendazole Veterinary Drug Sales by Country7.1.2 Europe Albendazole Veterinary Drug Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia 7.2 Europe Albendazole Veterinary Drug Market Facts & Figures by Type 7.3 Europe Albendazole Veterinary Drug Market Facts & Figures by Application 8 Asia Pacific 8.1 Asia Pacific Albendazole Veterinary Drug by Region8.1.1 Asia Pacific Albendazole Veterinary Drug Sales by Region8.1.2 Asia Pacific Albendazole Veterinary Drug Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam 8.2 Asia Pacific Albendazole Veterinary Drug Market Facts & Figures by Type 8.3 Asia Pacific Albendazole Veterinary Drug Market Facts & Figures by Application 9 Latin America 9.1 Latin America Albendazole Veterinary Drug by Country9.1.1 Latin America Albendazole Veterinary Drug Sales by Country9.1.2 Latin America Albendazole Veterinary Drug Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina 9.2 Central & South America Albendazole Veterinary Drug Market Facts & Figures by Type 9.3 Central & South America Albendazole Veterinary Drug Market Facts & Figures by Application 10 Middle East and Africa 10.1 Middle East and Africa Albendazole Veterinary Drug by Country10.1.1 Middle East and Africa Albendazole Veterinary Drug Sales by Country10.1.2 Middle East and Africa Albendazole Veterinary Drug Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 UAE 10.2 Middle East and Africa Albendazole Veterinary Drug Market Facts & Figures by Type 10.3 Middle East and Africa Albendazole Veterinary Drug Market Facts & Figures by Application 11 Company Profiles 11.1 GSK11.1.1 GSK Corporation Information11.1.2 GSK Description, Business Overview and Total Revenue11.1.3 GSK Sales, Revenue and Gross Margin (2015-2020)11.1.4 GSK Albendazole Veterinary Drug Products Offered11.1.5 GSK Recent Development 11.2 Sequent Scientific11.2.1 Sequent Scientific Corporation Information11.2.2 Sequent Scientific Description, Business Overview and Total Revenue11.2.3 Sequent Scientific Sales, Revenue and Gross Margin (2015-2020)11.2.4 Sequent Scientific Albendazole Veterinary Drug Products Offered11.2.5 Sequent Scientific Recent Development 11.3 Zoetis11.3.1 Zoetis Corporation Information11.3.2 Zoetis Description, Business Overview and Total Revenue11.3.3 Zoetis Sales, Revenue and Gross Margin (2015-2020)11.3.4 Zoetis Albendazole Veterinary Drug Products Offered11.3.5 Zoetis Recent Development 11.4 AdvaCare Pharma11.4.1 AdvaCare Pharma Corporation Information11.4.2 AdvaCare Pharma Description, Business Overview and Total Revenue11.4.3 AdvaCare Pharma Sales, Revenue and Gross Margin (2015-2020)11.4.4 AdvaCare Pharma Albendazole Veterinary Drug Products Offered11.4.5 AdvaCare Pharma Recent Development 11.5 Guangdong Tianbao Biological Pharmaceutical Co., Ltd.11.5.1 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Corporation Information11.5.2 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.5.3 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.5.4 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Albendazole Veterinary Drug Products Offered11.5.5 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Recent Development 11.6 Hanzhonghe Times Biotechnology Co., Ltd.11.6.1 Hanzhonghe Times Biotechnology Co., Ltd. Corporation Information11.6.2 Hanzhonghe Times Biotechnology Co., Ltd. Description, Business Overview and Total Revenue11.6.3 Hanzhonghe Times Biotechnology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.6.4 Hanzhonghe Times Biotechnology Co., Ltd. Albendazole Veterinary Drug Products Offered11.6.5 Hanzhonghe Times Biotechnology Co., Ltd. Recent Development 11.7 Yahui Medicine11.7.1 Yahui Medicine Corporation Information11.7.2 Yahui Medicine Description, Business Overview and Total Revenue11.7.3 Yahui Medicine Sales, Revenue and Gross Margin (2015-2020)11.7.4 Yahui Medicine Albendazole Veterinary Drug Products Offered11.7.5 Yahui Medicine Recent Development 11.8 Beijing Shengmu Biotechnology Co., Ltd.11.8.1 Beijing Shengmu Biotechnology Co., Ltd. Corporation Information11.8.2 Beijing Shengmu Biotechnology Co., Ltd. Description, Business Overview and Total Revenue11.8.3 Beijing Shengmu Biotechnology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.8.4 Beijing Shengmu Biotechnology Co., Ltd. Albendazole Veterinary Drug Products Offered11.8.5 Beijing Shengmu Biotechnology Co., Ltd. Recent Development 11.9 Hebei Huabang Biological Technology Co., Ltd.11.9.1 Hebei Huabang Biological Technology Co., Ltd. Corporation Information11.9.2 Hebei Huabang Biological Technology Co., Ltd. Description, Business Overview and Total Revenue11.9.3 Hebei Huabang Biological Technology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.9.4 Hebei Huabang Biological Technology Co., Ltd. Albendazole Veterinary Drug Products Offered11.9.5 Hebei Huabang Biological Technology Co., Ltd. Recent Development 11.10 Dongguan Meidehao Animal Pharmaceutical Co., Ltd.11.10.1 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Corporation Information11.10.2 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.10.3 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.10.4 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Albendazole Veterinary Drug Products Offered11.10.5 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Recent Development 11.1 GSK11.1.1 GSK Corporation Information11.1.2 GSK Description, Business Overview and Total Revenue11.1.3 GSK Sales, Revenue and Gross Margin (2015-2020)11.1.4 GSK Albendazole Veterinary Drug Products Offered11.1.5 GSK Recent Development 11.12 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd.11.12.1 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Corporation Information11.12.2 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.12.3 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.12.4 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Products Offered11.12.5 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Recent Development 11.13 Anhui Shenhui Agricultural Technology Co., Ltd.11.13.1 Anhui Shenhui Agricultural Technology Co., Ltd. Corporation Information11.13.2 Anhui Shenhui Agricultural Technology Co., Ltd. Description, Business Overview and Total Revenue11.13.3 Anhui Shenhui Agricultural Technology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.13.4 Anhui Shenhui Agricultural Technology Co., Ltd. Products Offered11.13.5 Anhui Shenhui Agricultural Technology Co., Ltd. Recent Development 11.14 Foshan Zhengdian Biotechnology Co., Ltd.11.14.1 Foshan Zhengdian Biotechnology Co., Ltd. Corporation Information11.14.2 Foshan Zhengdian Biotechnology Co., Ltd. Description, Business Overview and Total Revenue11.14.3 Foshan Zhengdian Biotechnology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.14.4 Foshan Zhengdian Biotechnology Co., Ltd. Products Offered11.14.5 Foshan Zhengdian Biotechnology Co., Ltd. Recent Development 11.15 Shanghai Shenya11.15.1 Shanghai Shenya Corporation Information11.15.2 Shanghai Shenya Description, Business Overview and Total Revenue11.15.3 Shanghai Shenya Sales, Revenue and Gross Margin (2015-2020)11.15.4 Shanghai Shenya Products Offered11.15.5 Shanghai Shenya Recent Development 11.16 Tianjin Bijia Pharmaceutical Co., Ltd.11.16.1 Tianjin Bijia Pharmaceutical Co., Ltd. Corporation Information11.16.2 Tianjin Bijia Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.16.3 Tianjin Bijia Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.16.4 Tianjin Bijia Pharmaceutical Co., Ltd. Products Offered11.16.5 Tianjin Bijia Pharmaceutical Co., Ltd. Recent Development 11.17 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province11.17.1 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Corporation Information11.17.2 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Description, Business Overview and Total Revenue11.17.3 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Sales, Revenue and Gross Margin (2015-2020)11.17.4 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Products Offered11.17.5 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Recent Development 11.18 Shimu Group11.18.1 Shimu Group Corporation Information11.18.2 Shimu Group Description, Business Overview and Total Revenue11.18.3 Shimu Group Sales, Revenue and Gross Margin (2015-2020)11.18.4 Shimu Group Products Offered11.18.5 Shimu Group Recent Development 11.19 CSTP11.19.1 CSTP Corporation Information11.19.2 CSTP Description, Business Overview and Total Revenue11.19.3 CSTP Sales, Revenue and Gross Margin (2015-2020)11.19.4 CSTP Products Offered11.19.5 CSTP Recent Development 11.20 Sneha Medicare11.20.1 Sneha Medicare Corporation Information11.20.2 Sneha Medicare Description, Business Overview and Total Revenue11.20.3 Sneha Medicare Sales, Revenue and Gross Margin (2015-2020)11.20.4 Sneha Medicare Products Offered11.20.5 Sneha Medicare Recent Development 12 Future Forecast by Regions (Countries) (2021-2026) 12.1 Albendazole Veterinary Drug Market Estimates and Projections by Region12.1.1 Global Albendazole Veterinary Drug Sales Forecast by Regions 2021-202612.1.2 Global Albendazole Veterinary Drug Revenue Forecast by Regions 2021-2026 12.2 North America Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.2.1 North America: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.2.2 North America: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.2.3 North America: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 12.3 Europe Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.3.1 Europe: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.3.2 Europe: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.3.3 Europe: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 12.4 Asia Pacific Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.4.2 Asia Pacific: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Albendazole Veterinary Drug Market Size Forecast by Region (2021-2026) 12.5 Latin America Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.5.1 Latin America: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.5.2 Latin America: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.5.3 Latin America: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 12.6 Middle East and Africa Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Market Opportunities and Drivers 13.2 Market Challenges 13.3 Market Risks/Restraints 13.4 Porters Five Forces Analysis 13.5 Primary Interviews with Key Albendazole Veterinary Drug Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Albendazole Veterinary Drug Customers 14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.

Read more:
Global Albendazole Veterinary Drug Market: Trends, Opportunities, Restraints, Key Manufacturers And Forecast During The Projected Period 2020-2026...

NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (iBio or the Company), a biotechnology innovator and biologics contract manufacturing organization, today announced that it has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. (Planet) for the development of Planets COVID-19 therapeutic candidate, ACE2-Fc.

ACE2-Fc is a recombinant protein comprised of human angiotensin converting enzyme 2 (ACE2) fused to a human immunoglobulin G Fc fragment (Fc). As an immunoadhesin, ACE2-Fc targets the coronavirus virions directly by using the ACE2 extracellular domain as a decoy to bind the spike protein and block infection of healthy cells, while the fused Fc domain prolongs the life of the protein in circulation. The design is expected to bring the benefit of a traditional neutralizing antibody while prospectively limiting the potential for viral escape given that ACE2 is also the target receptor for coronavirus for cell entry. Planets in vitro studies demonstrated that its ACE2-Fc blocks SARS-CoV-2 virus from infecting Vero E6 cells.

Under the terms of the agreement, iBio obtained an exclusive license to Planets ACE2-Fc. Planet is eligible to receive certain pre-specified payments upon achievement of clinical development milestones.

We see tremendous opportunity in our partnership with Planet to develop this novel immunoadhesin molecule as a potential COVID-19 disease treatment, said Tom Isett, Chairman & CEO of iBio. We believe the molecule may be effective against SARS-CoV-2 infection, and that it has the potential to be rapidly re-designed in the FastPharming System to address mutations in the current virus, if any, as well as future coronaviral diseases.

Elliot Fineman, Planets President and CEO, commented, iBio is an ideal partner for Planet, offering experience in manufacturing plant-based biopharmaceuticals and rapid scale-up capabilities. We are eager to support iBio in the pre-clinical development of ACE2-Fc.

About Planet Biotechnology Inc.

Scientists at Planet Biotechnology identify and develop promising antibodies and receptor/ligand-Fc fusion proteins for the treatment and prevention of disease. Planets anti-infective programs focus on tick-borne diseases, coronaviruses, and multi-drug resistant pathogens. The Company uses a plant-based expression system to rapidly produce its antibody and receptor/ligand-Fc products.

About iBios COVID-19 Programs

On March 11, 2020, the Company filed four provisional patent applications with the U.S. Patent and Trademark Office in support of its COVID-19 vaccine platforms. The Company subsequently announced its virus-like particle (VLP) program (IBIO-200) and LicKM-Subunit vaccine program (IBIO-201) on March 18, and June 3, 2020, respectively, and pre-clinical studies were subsequently initiated. On August 27, 2020, the Company secured exclusive worldwide rights to an ACE2-Fc antibody therapeutic from Planet Biotechnology, Inc. If any of the COVID-19 biopharmaceutical development program(s) move into clinical trials, iBio has the capability to manufacture product candidates at clinical and commercial scales in its 130,000 square foot facility in Bryan, Texas. Originally built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency (DARPA), iBios FastPharming Facility was part of the Blue Angel initiative to establish factories capable of rapid delivery of medical countermeasures in response to a disease pandemic.

About iBio, Inc.

iBio is a global leader in plant-based biologics manufacturing. Its FastPharming System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Companys subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services. iBios FastGlycaneering Development Service includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing proprietary products, which include IBIO-100 for the treatment of fibrotic diseases, as well as vaccines and therapeutics for COVID-19 disease. For more information, visit http://www.ibioinc.com.

FORWARD-LOOKING STATEMENTSCertain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the development of the novel immunoadhesin molecule as a potential COVID-19 disease treatment, the design bringing the benefits of a traditional neutralizing antibody while prospectively limiting the potential for viral escape given that ACE2 is also the target receptor for coronavirus for cell entry, the molecule being effective against SARS-CoV-2 infection, and that it has the potential to be rapidly re-designed in the FastPharming System to address mutations in the current virus, if any, as well as future coronaviral diseases. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the partnership with Planet being successful, the ability to develop the novel immunoadhesin molecule as a potential COVID-19 disease treatment and mutations in the current virus, the Companys ability to obtain regulatory approvals for commercialization of its product candidates, including its COVID-19 vaccines, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other factors discussed in the Companys Annual Report on Form 10-K for the year ended June 30, 2019 and the Companys subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contacts:

Stephen KilmeriBio, Inc.Investor Relations(646) 274-3580 skilmer@ibioinc.com

Read more:
iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic - GlobeNewswire

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Food Biotechnology market.

Trusted Business Insights presents an updated and Latest Study on Food Biotechnology Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Food Biotechnology market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Food Biotechnology Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Food Biotechnology MarketIndustry / Sector Trends

Global Food Biotechnology Market size was valued at over USD 23 billion in 2018 and is anticipated to witness over 10% CAGR up to 2025.

Increasing penetration of advanced technologies to develop new products by modifying plants, animals, and microorganisms genes to provide innovative solutions is driving the market growth. Shifting trends towards healthy lifestyles accompanied by a rise in processed food demand has urged the F&B manufacturers to improve the nutritional content in their products, thereby generating new growth opportunities for the biotech-based industry players. Further, there is a requirement to enhance the shelf life and taste of food by the use of encapsulation techniques and other ingredients.

Strong growth in functional food & beverages and dietary supplements industry is resulting in increased competitiveness, thus propelling the food biotechnology market revenue. As per CCI, the global nutraceutical market including functional F&B and dietary supplements is projected to reach USD 241 billion in 2019, observing around 7% CAGR from 2014 to 2019. Factors such as robust expansion of food industry and low-cost biotech services particular in developing countries has escalated the adoption of services.

Stringent government regulations to enhance product quality and transparency are among the foremost aspects attributing to food biotech solutions. Also, modifications in labeling regulations asking for a declaration of GMOs, allergens, and nutritional content is surging the industry share. Further, consumer-driven movements such as clean label has urged food manufacturers to improve the quality by using natural ingredients instead of artificial constituents.

Changes in climatic conditions over the years has resulted in increased production of genetically modified (GM) crops or ingredients through the use of biotech services. This provides plants with improved resistance to diseases, insecticides, and herbicides, as well as extending the shelf life of the produce. However, growth in the organic food industry can hamper the demand for GM crops, thus affecting the food biotechnology industry share.

Market Segmentation, Outlook & Regional Insights: Food Biotechnology Market

Food Biotechnology Market, By Type

Transgenic segment dominates the global market accounting for over 75% share in 2018. Increasing demand for genetically modified crops to enhance productivity in low producing or harsh climatic conditions will drive segment growth. According to ISAAA, the global utilized area for biotech crops increased from 148 million hectares in 2010 to 190 million hectares in 2017. Countries including the U.S., Brazil, Argentina, Canada, and India holds over 90% of the total area under GM crop cultivation. Farmers shifting from conventional seeds to bio-seeds to improve their profit margins will escalate the market growth.

Germany Food Biotechnology Market Size, By Type, 2018 (USD Million)

Food Biotechnology Market, By Application

Global food biotechnology market through animal segment holds over 34% share in 2018. Increasing necessity to enhance milk production in dairy cattle with growing demand will propel industry expansion. Robust growth in meat consumption such as processed meat accompanied by increasing consumer awareness on nutritional benefits will drive the biotech applications. As per FAO, global meat production is projected to increase, reach around 48MT by 2025. Further, testing services for developing products to suit the human dietary requirements will drive market development.

Global food biotechnology market through plants is projected to account for over USD 22 billion in 2025. The key growth factors include an increase in the development of GM crops with pesticide resistance and abiotic stress tolerance to increase the yield. Reduction in the arable land area will further shift the preference towards biotechnological products. Enhanced focus on innovation of new food ingredients will surge the business revenues. Strong application outlook of biotech solutions to produce high-quality crops and reduce the health risk will augment business expansion.

Food Biotechnology Market, By Region

North America market is anticipated to cross USD 12 billion by 2025. High investments on technological advancements coupled with high consumer spending on nutritious products will augment the industry share. The U.S. is the largest producer of genetically modified crops with 75 million hectares area for biotech crops. Further, the presence of large multinational corporations, increasing private and government R&D investments, supported by favourable government policies will fuel the market growth. Further, positive application outlook of genetically modified yeast in developing new alcoholic beverages will support regional growth.

Asia Pacific Food Biotechnology Market, By Country, 2018 & 2025, (USD Million)

Asia Pacific food biotechnology market is projected to witness over 11% CAGR from 2019 to 2025. Countries including China, India, and Japan together dominate the regional market share. The demand for dietary supplements is increasing due to a shifting trend towards healthy lifestyles, thus increasing the demand for nutritional ingredients. Also, product innovations supported by the rise in per capita income will drive the biotech solutions on health foods. Further, the necessity to augment the agricultural output owing to the rise in population, along with severe climatic variations will drive the biotechnology industry share.

Key Players, Recent Developments & Sector Viewpoints: Food Biotechnology Market

Global market is competitive due to the presence of large multinationals and regional players. Key industry participants in market include BASF SE, Bayer CropScience AG, AquaBounty Technologies, ABS Global, Dow AgroSciences LLC, Arcadia Biosciences, Camson Bio Technologies Ltd, BDF Ingredients Zuchem, and Monsanto. Product development, geographic expansion, mergers, acquisitions, and collaborations are among the key strategies observed in the industry. For instance, in 2017, Bayer and Ginkgo Bioworks announced to launch a company to developing new technologies for engineering the plant microbiome.

Industry Viewpoint

Food biotechnology market is driven by the requirement for improving the productivity and quality of the edible items by altering genes. Growth in the food & beverages industry, increasing population, rising disposable incomes, and health awareness are among the major factors creating a long-term positive impact. Biotechnological product innovations among food manufacturers will provide lucrative opportunities for business growth. North America and Europe are among the early adopters of biotech services, however developing regions are also expected to implement advanced solutions in food industry. The penetration rate is high in Asia Pacific owing to strong R&D investments and the necessity for increasing the food productivity and animal milk output

Key Insights Covered: Exhaustive Food Biotechnology Market1. Market size (sales, revenue and growth rate) of Food Biotechnology industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Food Biotechnology industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Food Biotechnology industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Food Biotechnology industry.

Research Methodology: Food Biotechnology Market

Looking for more? Check out our repository for all available reports on Food Biotechnology in related sectors.

Quick Read Table of Contents of this Report @ Food Biotechnology Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Go here to read the rest:
Food Biotechnology Market: Trends, Applications, Industry Competitive Analysis, Growth,Forecast: 2019 to 2029 - The Scarlet

A rating of 95 puts Cytokinetics, Inc. (CYTK) near the top of the Biotechnology industry according to InvestorsObserver. Cytokinetics, Inc.'s score of 95 means it scores higher than 95% of stocks in the industry. Cytokinetics, Inc. also received an overall rating of 77, putting it above 77% of all stocks. Biotechnology is ranked 26 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 77 means the stock is more attractive than 77 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Cytokinetics, Inc. (CYTK) stock is trading at $24.50 as of 2:24 PM on Friday, Aug 28, a gain of $0.86, or 3.64% from the previous closing price of $23.64. The stock has traded between $23.65 and $24.95 so far today. Volume today is 824,667 compared to average volume of 1,027,773.

To see the top 5 stocks in Biotechnology click here.

Visit link:
Is Cytokinetics, Inc. (CYTK) the Top Pick in the Biotechnology Industry? - InvestorsObserver

The 62 rating InvestorsObserver gives to Trevena Inc (TRVN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, TRVNs 62 overall rating means the stock scores better than 62 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Trevena Inc (TRVN) stock is trading at $1.68 as of 9:51 AM on Friday, Aug 28, a rise of $0.11, or 7.01% from the previous closing price of $1.57. The stock has traded between $1.68 and $1.89 so far today. Volume today is low. So far 3,619,286 shares have traded compared to average volume of 15,506,572 shares.

To see the top 5 stocks in Biotechnology click here.

Continued here:
Is Trevena Inc (TRVN) The Right Choice in Biotechnology? - InvestorsObserver

The 41 rating InvestorsObserver gives to Tyme Technologies Inc (TYME) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 33 percent of stocks in the Biotechnology industry, TYMEs 41 overall rating means the stock scores better than 41 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 41 would rank higher than 41 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Tyme Technologies Inc (TYME) stock has fallen -5.26% while the S&P 500 has gained 0.33% as of 2:25 PM on Friday, Aug 28. TYME is down -$0.06 from the previous closing price of $1.14 on volume of 1,253,542 shares. Over the past year the S&P 500 is up 19.54% while TYME is down -6.90%. TYME lost -$0.23 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read this article:
Is Tyme Technologies Inc (TYME) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Syros Pharmaceuticals Inc (SYRS) is near the middle in its industry group according to InvestorsObserver. SYRS gets an overall rating of 57. That means it scores higher than 57 percent of stocks. Syros Pharmaceuticals Inc gets a 65 rank in the Biotechnology industry. Biotechnology is number 26 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 57 means the stock is more attractive than 57 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Syros Pharmaceuticals Inc (SYRS) stock is down -2.84% while the S&P 500 is higher by 0.33% as of 2:23 PM on Friday, Aug 28. SYRS has fallen -$0.38 from the previous closing price of $13.39 on volume of 312,289 shares. Over the past year the S&P 500 is up 19.54% while SYRS is higher by 18.60%. SYRS lost -$1.69 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Syros Pharmaceuticals Inc click here.

Go here to see the original:
Is Syros Pharmaceuticals Inc (SYRS) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The Biotechnology market demand is anticipated to flourish during the forecast period 2018-2026. The report offers information related to import and export, along with the current business chain in the market at the global level. This report provides an in-depth overview of the Biotechnology market. This includes market characteristics, consisting of segmentation, market share, trends and strategies for this market. The Market Size section provides historical forecasts of market growth and future. An in-depth analysis of the major companies operating in the market is also mentioned in this research report.

Get FREE PDF Brochure Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/4025

The global Biotechnology market is segmented on the basis of type and application.

It also provides market size and forecast estimates from the year 2018 to 2026 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and South America (SAM). The Biotechnology market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of top countries globally along with the current trend and opportunities prevailing in the region.

A thorough examination of the Biotechnology market includes each and every aspect, which begins with knowing the market, speaking with clients, and evaluating the complete data of the global market. For more clarification, the global market is segmented on the basis of the manufacture of the kind of products, and their applications. The report also delivers information as per the regions based on the geographical classification of the global Biotechnology market. The dynamic foundation of the global market is based on the calculation of product supply in different markets, their revenues, capability, and a chain of production.

Qualitative information will discuss the key factors driving the restraining the growth of the market, and the possible growth opportunities of the market, regulatory scenario, value chain & supply chain analysis, export & import analysis, attractive investment proposition, and Porters 5 Forces analysis among others will be a part of qualitative information.

Competitive Section

Key players operating the Biotechnology market are Abbott Laboratories, Amgen Inc., GlaxoSmithKline, Johnson and Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Inc., Roche, and Sanofi Aventis.

Furthermore, this study will help our clients solve the following issues:

Market dynamics- The study foresees dynamics of industries by using core analytical and unconventional market research approaches. This will help clients to use this insight provided to maneuver themselves through market uncertainties and disruptions

Identifying key cannibalizes Strong substitute for a product or service is the most prominent threat. Our clients can identify key cannibalizes of a market, by procuring our research. This helps them in aligning their new product development/launch strategies in advance

Spotting emerging trends-Our Ecosystem offering helps clients to spot upcoming hot market trends. We also track possible impact and disruptions which a market would witness by a particular emerging trend. Our proactive analysis helps clients to have early mover advantage

Interrelated opportunities- This report will allow clients to make decisions based on data, thereby increasing the chances that the strategies will perform better if not best in the real world

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000Quick [emailprotected] https://www.coherentmarketinsights.com/insight/buy-now/4025

All in all, the Biotechnology market research study elucidates a detailed evaluation of this business and projects this industry to register a commendable growth rate in the forthcoming years. The Biotechnology market analysis report also delivers important insights with respect to aspects such as the volume of sales, valuation forecast, market size, and the market competition trends as well as the market concentration rate.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: [emailprotected]United States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

More here:
Biotechnology Market Size Research, Business Opportunities, Top Manufacture, Industry Growth, Industry Share Report, Regional Analysis and Global...

The 65 rating InvestorsObserver gives to Arena Pharmaceuticals, Inc. (ARNA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 82 percent of stocks in the Biotechnology industry, ARNAs 65 overall rating means the stock scores better than 65 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Arena Pharmaceuticals, Inc. (ARNA) stock is trading at $70.03 as of 2:24 PM on Friday, Aug 28, a gain of $0.90, or 1.3% from the previous closing price of $69.13. Volume today is above average. So far 660,189 shares have traded compared to average volume of 470,186 shares. The stock has traded between $68.58 and $70.77 so far today.

To screen for more stocks like ARNA click here.

Follow this link:
Where Does Arena Pharmaceuticals, Inc. (ARNA) Stock Fall in the Biotechnology Field? - InvestorsObserver

Tauriga Sciences Inc (TAUG) is around the bottom of the Biotechnology industry according to InvestorsObserver. TAUG received an overall rating of 24, which means that it scores higher than 24 percent of all stocks. Tauriga Sciences Inc also achieved a score of 11 in the Biotechnology industry, putting it above 11 percent of Biotechnology stocks. Biotechnology is ranked 24 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 24 would rank higher than 24 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Tauriga Sciences Inc (TAUG) stock is flat 9.09% while the S&P 500 has risen 0.16% as of 1:43 PM on Thursday, Aug 27. TAUG is unchanged $0.00 from the previous closing price of $0.03 on volume of 769,766 shares. Over the past year the S&P 500 is up 20.64% while TAUG has risen 33.33%. TAUG lost -$0.04 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Tauriga Sciences Inc click here.

Originally posted here:
Is Tauriga Sciences Inc (TAUG) a Winner in the Biotechnology Industry? - InvestorsObserver

The latest research on the Global Food Biotechnology Market that covers growth factor, future trends, and focuses on overall knowledge that can help to make decisions on the current market situation. Food Biotechnology report provides information on Size, Type, Service, Output, Revenue, Growth Rate, Gross Margin, and opportunities with potential risk analysis. The Food Biotechnology research study defines top company profiles with trends around the world present in the market. The report also discusses financial developments with the effect of COVID-19 on the market of Food Biotechnology across years. TheFood Biotechnology research executes financial adjustments that occur on the market year after year, with details on future opportunities and risks to keep you ahead of the competitors.Food Biotechnology market research has driven you to expand your company.

Major Players Covered in this Report are:

ABS Global, Arcadia Biosciences, AquaBounty Technologies, BASF Plant Science, Bayer CropScience AG, Camson Bio Technologies Ltd, Dow AgroSciences LLC, DuPont Pioneer, Evogene Ltd, Hy-Line International, KWS Group, Monsanto, Origin Agritech Limited, Syngenta AG

To Request an Exclusive Sample Report for Food Biotechnology Market @ https://www.marketgrowthinsight.com/sample/132600

Scope of the Food Biotechnology Market Report:

The demand for Food Biotechnology is projected to expand, during the forecast period, from USD million in 2020 to USD million by 2025. The global market report is a systematic study that focuses on the overall demand structure, development trends, business models and business of top countries in the global market for Food Biotechnology. The study focuses on well-known global Food Biotechnology suppliers, market segments, competition and the macro market.

The Food Biotechnology study focuses on the prospects for growth, constraints, and market analysis. The research offers Porters five-force Food Biotechnology industry analysis to understand the effect of various factors such as supplier power bargaining, competitor competition, new entrant challenge, competitor risk, and buyer bargaining power on the market.

Market Segmentation:

A brief overview of the global Food Biotechnology market has been presented according to the most recent report. TheFood Biotechnology evaluation notes the concept of service/product in many end-user sectors along with other implementations of these goods or services. The Global Food Biotechnology Market Report presented a thorough assessment of the latest industry developments, extensive regional analysis, and competitive analysis for the 2020-2025 review period.

Geographically, the detailed analysis of consumption, revenue, Food Biotechnology market share and growth rate, historic and forecast (2015-2025) of the following regions are covered:

North America (United States, Canada, Mexico)Europe (Germany, UK, France, Italy, Spain, Russia, Others)Asia-Pacific (China, Australia,South Korea,Japan, India, Southeast Asia, Others)Middle East and Africa (UAE, Saudi Arabia, Egypt, South Africa, Nigeria, Others)South America (Brazil, Argentina, Columbia, Chile, Others)

Ask for Discount on this Premium Report @ https://www.marketgrowthinsight.com/discount/132600

In this study, the years considered to estimate the market size of Food Biotechnology are as follows:

KEY QUESTIONS ANSWERED:

For More Details On this Report: https://www.marketgrowthinsight.com/inquiry/132600

About Us-

Market Growth Insight 100% Subsidiary of Exltech Solutions India, is a one stop solution for market research reports in various business categories. We are serving 100+ clients with 30000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide-ranging analysis and latest industry trends.

Contact Us:

Direct Line: +1 3477675477 (US)Email: [emailprotected]Web:https://www.marketgrowthinsight.com

Read more:
Food Biotechnology Market Research Report is Projected to Witness Considerable Growth by 2025 - thedailychronicle.in

Odonate Therapeutics Inc (ODT) is around the bottom of the Biotechnology industry according to InvestorsObserver. ODT received an overall rating of 33, which means that it scores higher than 33 percent of all stocks. Odonate Therapeutics Inc also achieved a score of 20 in the Biotechnology industry, putting it above 20 percent of Biotechnology stocks. Biotechnology is ranked 25 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 33 means the stock is more attractive than 33 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Odonate Therapeutics Inc (ODT) stock is trading at $17.65 as of 3:06 PM on Wednesday, Aug 26, a gain of $0.15, or 0.86% from the previous closing price of $17.50. Volume today is more active than usual. So far 551,544 shares have traded compared to average volume of 251,597 shares. The stock has traded between $16.85 and $17.98 so far today.

To see InvestorsObserver's Sentiment Score for Odonate Therapeutics Inc click here.

Read the original here:
Is Odonate Therapeutics Inc (ODT) The Right Choice in Biotechnology? - InvestorsObserver

Vir Biotechnology, Inc. (NASDAQ:VIR) went down by -5.86% from its latest closing price when compared to the 1-year high value of $75.00 and move down -82.48%, while VIR stocks collected -20.79% of loss with the last five trading sessions. Press Release reported on 08/20/20 that Vir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress(TM)

Vir Biotechnology, Inc. (NASDAQ:VIR) 4 of the analysts out of 7 who provided ratings for Vir Biotechnology, Inc. stocks as a buy while 0 as overweight, 1 rated it as hold and 1 as sell. The average price we get from analysts is $49.17 which is $2.9 above current price. VIR currently has a short float of 3.60% and public float of 109.09M with average trading volume of 1.27M shares.

VIR stocks went down by -20.79% for the week, with the monthly drop of -13.42% and a quarterly performance of 20.25%. The simple moving average for the period of the last 20 days is -18.00% for VIR stocks with the simple moving average of 32.99% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with Needham repeating the rating for VIR shares by setting it to Buy. The predicted price for VIR socks in the upcoming period according to Needham is $62 based on the research report published on August 20, 2020.

JP Morgan, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Underweight according to the report published on March 19, 2020.

Goldman gave Neutral rating to VIR stocks, setting the target price at $26 in the report published on March 13, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -45.20% of loss for the given period.

The stock volatility was left at 6.78%, however, within the period of a single month, the volatility rate increased by 10.34%, while the shares sank at the distance of -12.66% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +10.84% upper at the present time.

In the course of the last 5 trading sessions, VIR went down by -20.79%, which changed the moving average for the period of 200 days to the total of +209.72% of gains for the stock in comparison to the 20-day moving average settled at $49.83. In addition, Vir Biotechnology, Inc. saw 226.84% in overturn over the period of a single year with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at Vir Biotechnology, Inc. (VIR), starting from Pang Phillip, who sold 12,500 shares at the price of $50.95 back on Aug 19. After this action, Rushing now owns 29,777 shares of Vir Biotechnology, Inc., valued at $636,855 with the latest closing price.

Virgin Herbert, the EVP, Research & CSO of Vir Biotechnology, Inc., sold 7,900 shares at the value of $51.08 during a trade that took place back on Aug 11, which means that Virgin Herbert is holding 0 shares at the value of $403,563 based on the most recent closing price.

The current profitability levels are settled at -2144.35 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -62.52, while invested capital returns managed to touch -62.97. Equity return holds the value -81.10%, with -42.30% for asset returns.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

Originally posted here:
What Vir Biotechnology, Inc. (VIR) Doesnt Want You to Know - The News Heater

Ibio Inc (IBIO) is around the bottom of the Biotechnology industry according to InvestorsObserver. IBIO received an overall rating of 34, which means that it scores higher than 34 percent of all stocks. Ibio Inc also achieved a score of 21 in the Biotechnology industry, putting it above 21 percent of Biotechnology stocks. Biotechnology is ranked 31 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Ibio Inc (IBIO) stock is trading at $2.58 as of 10:05 AM on Tuesday, Aug 25, a rise of $0.37, or 16.52% from the previous closing price of $2.21. The stock has traded between $2.21 and $2.63 so far today. Volume today is less active than usual. So far 21,135,227 shares have traded compared to average volume of 45,691,093 shares.

To screen for more stocks like IBIO click here.

Continue reading here:
Is Ibio Inc (IBIO) the Top Pick in the Biotechnology Industry? - InvestorsObserver